Your browser is no longer supported. Please, upgrade your browser.
INO Inovio Pharmaceuticals, Inc. daily Stock Chart
Inovio Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.04 Insider Own3.80% Shs Outstand97.37M Perf Week-3.31%
Market Cap370.01M Forward P/E- EPS next Y-1.09 Insider Trans-0.27% Shs Float91.50M Perf Month4.97%
Income-97.00M PEG- EPS next Q-0.26 Inst Own37.40% Short Float14.74% Perf Quarter-20.50%
Sales30.50M P/S12.13 EPS this Y2.90% Inst Trans0.39% Short Ratio9.52 Perf Half Y-30.15%
Book/sh0.90 P/B4.22 EPS next Y-11.20% ROA-65.30% Target Price10.75 Perf Year-18.63%
Cash/sh0.83 P/C4.56 EPS next 5Y0.00% ROE-93.50% 52W Range3.02 - 6.30 Perf YTD-5.00%
Dividend- P/FCF- EPS past 5Y6.10% ROI-110.80% 52W High-38.97% Beta1.71
Dividend %- Quick Ratio2.50 Sales past 5Y17.70% Gross Margin- 52W Low27.32% ATR0.16
Employees281 Current Ratio2.50 Sales Q/Q-71.60% Oper. Margin- RSI (14)50.80 Volatility4.49% 3.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-44.20% Profit Margin- Rel Volume0.42 Prev Close3.80
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume1.42M Price3.85
Recom1.60 SMA20-0.26% SMA502.09% SMA200-16.11% Volume391,837 Change1.18%
Feb-15-18Reiterated Maxim Group Buy $12 → $8
Oct-18-17Initiated RBC Capital Mkts Outperform $11
Sep-06-17Initiated Citigroup Buy $10
Jun-08-17Upgrade Piper Jaffray Neutral → Overweight
May-24-17Reiterated Maxim Group Buy $10 → $12
Mar-16-17Upgrade Maxim Group Hold → Buy $10
Mar-16-17Downgrade Piper Jaffray Overweight → Neutral
Nov-07-16Initiated Aegis Capital Buy
Aug-09-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Stifel Buy $19 → $13
Jan-05-16Reiterated Maxim Group Buy $23 → $14
Sep-09-15Reiterated Maxim Group Buy $20 → $23
Mar-12-15Initiated H.C. Wainwright Buy $17
Jul-24-14Upgrade Aegis Capital Hold → Buy $10 → $19
May-07-14Initiated Stifel Buy $4
Mar-18-14Reiterated Maxim Group Buy $3 → $6
Jan-24-14Reiterated Brean Capital Buy $3 → $4
Aug-16-13Downgrade Aegis Capital Buy → Hold
Jul-09-13Reiterated Maxim Group Buy $1 → $2
Mar-11-13Initiated Aegis Capital Buy $1.50
Apr-18-19 02:43PM  Cover story: Joseph Kim's art of the bio-deal American City Business Journals
09:00AM  Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs) in a Peer-reviewed Journal PR Newswire
06:00AM  Inovio- A Biotech Bet for New World Investors MoneyShow
Apr-17-19 09:00AM  Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress PR Newswire -5.34%
Apr-11-19 09:30AM  Inovio (INO) Up 10.7% Since Last Earnings Report: Can It Continue? Zacks
Apr-09-19 11:37AM  One Thing To Remember About The Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Share Price Simply Wall St.
10:30AM  Inovio Earns 3rd Milestone Fee From AstraZeneca for MEDI0457 Zacks
Apr-08-19 09:00AM  Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development PR Newswire
Apr-04-19 10:36AM  Inovio's HPV Candidate Shows Efficacy in Pilot Study, Stock Up Zacks
Apr-03-19 09:00AM  Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study PR Newswire
Apr-02-19 10:51AM  Inovio Closes Enrollment in Brain Cancer Study Before Time Zacks
07:45AM  Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR PR Newswire
Apr-01-19 07:45AM  Inovio Completes Enrollment Ahead of Schedule In Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor PR Newswire
Mar-27-19 07:45AM  Inovio Pharmaceuticals to Present at H.C. Wainwright Global Life Sciences Conference in London, UK PR Newswire
Mar-25-19 07:45AM  Inovio Appoints Global Commercial Leader to its Board of Directors PR Newswire
Mar-21-19 09:11AM  Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases PR Newswire
08:42AM  Inovio Pharmaceuticals stock up 9% after company announces positive data from Phase 1 trial of Ebola vaccine MarketWatch
08:18AM  Inovio's Ebola Vaccine Delivered Intradermally Demonstrates 100% Immunogenicity in a Clinical Study Published in The Journal of Infectious Diseases PR Newswire
Mar-20-19 12:35AM  Edited Transcript of INO earnings conference call or presentation 12-Mar-19 8:30pm GMT Thomson Reuters StreetEvents
Mar-18-19 11:28AM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
Mar-13-19 10:03AM  Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down Zacks
05:04AM  Inovio Pharmaceuticals (INO) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-12-19 06:15PM  Inovio Pharmaceuticals (INO) Reports Q4 Loss, Lags Revenue Estimates Zacks
05:19PM  Inovio Pharmaceuticals Earnings: INO Stock Dips as Q4 Revenue Declines InvestorPlace
05:10PM  Inovio: 4Q Earnings Snapshot Associated Press
04:10PM  Inovio Pharmaceuticals Reports 2018 Fourth Quarter and Year-End Financial Results PR Newswire
11:59AM  C-suite shuffle at Inovio Pharmaceuticals American City Business Journals
08:00AM  Inovio Appoints Chief Operating Officer; Announces Strategic Management Changes PR Newswire
Mar-08-19 02:16PM  Imagine Owning Inovio Pharmaceuticals (NASDAQ:INO) And Trying To Stomach The 75% Share Price Drop Simply Wall St. -5.92%
Mar-06-19 08:42AM  Why Inovio Pharmaceuticals Stock Broke Down in February Motley Fool -5.26%
Mar-05-19 08:00AM  Inovio Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on March 12, 2019 PR Newswire
Mar-04-19 08:00AM  Inovio Initiates REVEAL 2 Global Phase 3 Clinical Study For the Treatment of HPV-Related Cervical Pre-cancer PR Newswire
Mar-01-19 11:22AM  Inovio Pharmaceuticals Completes Sale of Additional Convertible Senior Notes PR Newswire
Feb-28-19 10:17AM  Inovio spinoff developing patient-specific cancer therapies raises $10.5M American City Business Journals
Feb-25-19 12:41PM  Small Cap Winners And Losers From Last Week Benzinga
Feb-21-19 08:00AM  Geneos Therapeutics Secures $10.5 Million in Series A Financing to Develop the Next Generation of Neoantigen-Targeting Cancer Immunotherapies PR Newswire
Feb-20-19 08:00AM  Inovio Announces First Subject Dosed with its DNA-Encoded Monoclonal Antibody (dMAb) In First-Ever Human Trial PR Newswire
07:30AM  Recent Analysis Shows NVIDIA, Molson Coors Brewing, Invacare, The Blackstone Group, Inovio Pharmaceuticals, and Tech Data Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-15-19 09:47AM  Montco biopharm firm plans $65M note sale; stock drops by 22 percent American City Business Journals
Feb-14-19 12:00PM  Here's Why Inovio Pharmaceuticals Is Getting Beaten Down Today Motley Fool -21.15%
07:50AM  The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial Benzinga
07:00AM  Inovio Pharmaceuticals Prices $65.0 Million Convertible Senior Notes Offering PR Newswire
Feb-13-19 04:01PM  Inovio Pharmaceuticals Announces Proposed Convertible Senior Notes Offering PR Newswire
Jan-28-19 05:26PM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks -5.69%
Jan-24-19 01:30PM  4 Pharma Stocks Leading Thursday's Bull Charge ACCESSWIRE
08:47AM  Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor PR Newswire
08:32AM  Inovio Reports 2nd Patient Achieving Full Remission from HPV-Related Head & Neck Cancer after Treatment with Synthetic DNA Vaccine and a PD-1 Checkpoint Inhibitor PR Newswire
Jan-23-19 12:19PM  Have Insiders Been Selling Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Shares? Simply Wall St.
Jan-15-19 08:00AM  Inovio's dMAb PD-1 Checkpoint Inhibitors Demonstrate Higher and More Prolonged Expression Compared to Native Pembrolizumab and Nivolumab Sequences In Preclinical Studies PR Newswire
Jan-14-19 10:22AM  Can Inovio Pharmaceuticals Stock Keep Bounding Higher? Motley Fool -6.82%
Jan-10-19 10:00AM  Acorda (ACOR) Plans to Launch Inbrija in Q1: What to Expect Zacks
Jan-09-19 09:50AM  Amgen's Osteoporosis Candidate Evenity Gets Approval in Japan Zacks
Jan-07-19 10:09AM  Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed Zacks +7.17%
08:00AM  Inovio's DNA-Encoded Monoclonal Antibody (dMAb) Platform Leaps Forward with First-in-Human Trial PR Newswire
08:00AM  Inovio's DNA-Encoded Monoclonal Antibody (dMAb(TM)) Platform Leaps Forward with First-in-Human Trial PR Newswire
Jan-04-19 06:29PM  Jazz Inks Deal with Codiak to Develop Exosome Therapeutics Zacks +7.48%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
Jan-03-19 09:30AM  Novo Nordisk Boasts Strong Diabetes Presence and Pipeline Zacks
08:00AM  Inovio Announces Appointments to its Board of Directors PR Newswire
Dec-28-18 08:29AM  Horizon Pharma's Ravicti Gets FDA Nod for Expanded Age Group Zacks
Dec-27-18 08:25AM  AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions Zacks
Dec-17-18 12:59PM  Do Insiders Own Lots Of Shares In Inovio Pharmaceuticals, Inc. (NASDAQ:INO)? Simply Wall St.
Dec-08-18 06:19PM  RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy? Insider Monkey
09:30AM  Why Is Inovio (INO) Down 0.6% Since Last Earnings Report? Zacks
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
Dec-04-18 08:00AM  Inovio Announces Initiation of MD Andersons HPV-Related Cancers Moon Shot Phase 2 Trial in New HPV Indications GlobeNewswire
Nov-26-18 08:50AM  Consolidated Research: 2018 Summary Expectations for Ur Energy, SilverCrest Metals, Norwegian Cruise Line, Inovio Pharmaceuticals, Spok, and SunLink Health Fundamental Analysis, Key Performance Indications GlobeNewswire
08:00AM  Inovio Further Demonstrates Potency of its DNA-Encoded Monoclonal Antibody (dMAb) Platform in Three Preclinical Publications and Prepares for First Clinical Trial in Early 2019 GlobeNewswire
Nov-20-18 09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
Nov-15-18 08:00AM  Inovio Prepares for Growth & Commercialization With Leadership Appointments GlobeNewswire
Nov-14-18 10:15AM  Merck Starts Rolling BLA Submission for Ebola Vaccine V920 Zacks
Nov-09-18 10:34AM  Inovio (INO) Q3 Loss Narrower Than Expected, Revenues Meet Zacks
Nov-08-18 11:36PM  Edited Transcript of INO earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
07:35PM  Inovio Pharmaceuticals (INO) Reports Q3 Loss, Lags Revenue Estimates Zacks
06:30PM  Inovio: 3Q Earnings Snapshot Associated Press
04:05PM  Inovio Pharmaceuticals Reports 2018 Third Quarter Financial Results GlobeNewswire
Nov-07-18 02:56PM  What does Inovio Pharmaceuticals Incs (NASDAQ:INO) Balance Sheet Tell Us About Its Future? Simply Wall St.
Nov-05-18 08:00AM  Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences GlobeNewswire
Oct-25-18 08:00AM  Inovio HIV Vaccine PENNVAX®-GP Delivered Intradermally Generated Robust, Long-Term Best-In-Class Antibody and T Cell Immune Responses GlobeNewswire
Oct-24-18 08:00AM  Inovio Pharmaceuticals to Report Third Quarter 2018 Financial Results on November 8, 2018 GlobeNewswire -8.24%
Oct-22-18 08:00AM  Inovio Presents Progression Free Survival & PSA Doubling Time Improvements in Prostate Cancer Patients Treated with INO-5150 GlobeNewswire
Oct-17-18 08:00AM  Inovios DNA-Encoded Monoclonal Antibody (dMAb) Platform Moves Ahead with Positive Data, Patents and Grants GlobeNewswire
Oct-15-18 08:00AM  Inovios Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies GlobeNewswire
Oct-09-18 07:50AM  Report: Developing Opportunities within Adamis Pharmaceuticals, Cass Information, Celldex Therapeutics, Par Pacific, Inovio Pharmaceuticals, and Liberty Global Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 08:00AM  Inovio Successfully Develops First DNA-Encoded Monoclonal Antibody (dMAb) Checkpoint Inhibitor and Demonstrates Tumor Shrinkage in Preclinical Studies GlobeNewswire
Oct-05-18 10:30AM  Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up Zacks
Oct-03-18 08:00AM  Todays Research Reports on Stocks to Watch: Inovio Pharmaceuticals and vTV Therapeutics ACCESSWIRE
Oct-02-18 12:18PM  Why Inovio Pharmaceuticals, Inc. Stock Is Soaring Today Motley Fool +14.21%
08:00AM  Major Cancer Journal Highlights Data From An Inovio-Sponsored Trial In Which A Patient Achieved Full Remission After Dosing With DNA Immunotherapy and Checkpoint Inhibitor GlobeNewswire
Sep-23-18 04:10PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-18-18 10:30AM  Undervalued Cannabis and Biotech Stocks ACCESSWIRE
07:31AM  Inovio Pharmaceuticals (INO): Moving Average Crossover Alert Zacks
Sep-17-18 08:00AM  Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges GlobeNewswire
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-11-18 06:26PM  Edited Transcript of INO earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Sep-10-18 10:29AM  Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth Zacks
Sep-07-18 01:44PM  How Inovio Pharmaceuticals Inc (NASDAQ:INO) Can Impact Your Portfolio Volatility Simply Wall St.
11:03AM  Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine Zacks
Sep-06-18 06:00AM  Why Inovio Pharmaceuticals Inc. Stock Bolted Higher in August Motley Fool
Sep-05-18 08:00AM  Inovio Doses 1st Subject in Phase 1/2 Clinical Trial For Vaccine Against Deadly MERS Infection GlobeNewswire
Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; bladder cancer; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include MedImmune, Limited; The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; and Coalition for Epidemic Preparedness Innovations. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DHILLON AVTAR SDirectorDec 06Option Exercise2.0025,00050,000106,002Dec 06 05:17 PM
KIES PETERCFONov 29Option Exercise2.0010,00120,00272,089Nov 30 05:27 PM
KIES PETERCFONov 29Sale5.2810,00152,80562,088Nov 30 05:27 PM
Kim Jong JosephChief Executive OfficerSep 12Option Exercise5.0849,060249,2252,357,554Sep 14 05:12 PM
Kim Jong JosephChief Executive OfficerSep 12Sale5.3749,060263,4522,308,494Sep 14 05:12 PM
KIES PETERCFOJul 10Sale4.4510,00044,50062,088Jul 11 05:05 PM
KIES PETERCFOJul 09Option Exercise4.2415,00063,60097,088Jul 11 05:05 PM
KIES PETERCFOJul 09Sale4.4325,000110,75072,088Jul 11 05:05 PM